Company news
Novamind Inc news in 2022
Novamind Inc's news releases, calls and decks from 2022, newest first.
CSE Bulletin: Delist -Novamind Inc. (NM)
June 13, 2022
Novamind Obtains Final Order for Plan of Arrangement from the Supreme Court of British Columbia and Completes Acquisition by Numinus Wellness Inc.
June 10, 2022
Novamind Shareholders Approve Proposed Acquisition by Numinus
June 8, 2022
Novamind Announces New Patient Financing Options
June 2, 2022
Novamind Reports Fiscal Q3 2022 Financial Results and Operating Highlights
May 31, 2022
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Shareholders of Novamind Vote FOR the Proposed Plan of Arrangement
May 27, 2022
Novamind Launches Group Psychedelic Treatment for Frontline Workers
May 19, 2022
Novamind Files Management Information Circular for Special Meeting of Shareholders and Announces Receipt of Interim Court Order for Plan of Arrangement
May 11, 2022
Novamind to Host Bionomics' PREVAIL Trial for Acute Treatment of Social Anxiety Disorder
May 10, 2022
Novamind Announces Virtual Group Health Coaching
May 2, 2022
Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
April 12, 2022
Novamind Opens 8th Integrative Psychiatry Clinic
April 6, 2022
Novamind Partner to Acquire Specialized Ibogaine Group in Brazil
March 31, 2022
Novamind Expands Group Therapy Model
March 24, 2022
Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
March 16, 2022
Novamind Grants Restricted Share Units
March 11, 2022
Novamind to Conduct Phase II Psilocybin Trial for Major Depressive Disorder
March 9, 2022
Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights
March 1, 2022
Novamind Publishes Psychedelic Therapy Patient Case Studies
February 22, 2022
Novamind Advances Clinical Pilot for Frontline KAP
February 16, 2022
Novamind Participates in Alto Neuroscience Phase II Clinical Trial for MDD and PTSD
February 9, 2022
Novamind Appoints Prakash Gowd as Chief Operating Officer
February 8, 2022
Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients
February 3, 2022
Novamind Announces Closing of CAD$5 Million Private Placement with Institutional Investor
January 25, 2022
Novamind Announces CAD$5 Million Private Placement with Institutional Investor
January 24, 2022
Novamind to Participate in Citi's Psychedelic Drug Video Call Series
January 20, 2022
Novamind Closes Arizona Acquisition
January 18, 2022
Novamind Hosts Pioneering Psychedelic Clinical Trial for Opioid Use Disorder
January 13, 2022
Novamind Unveils New Design Concept for Clinics
January 5, 2022